Teva Loses Bid to Have Patent-Delisting Decision Reheard (1)

Teva Pharmaceutical Industries Ltd. failed to convince the Federal Circuit to reconsider a December ruling that five patents related to its ProAir HFA asthma inhaler must be delisted from the FDA’s registry of approved drugs.

In a win for generic-drug maker Amneal Pharmaceuticals Inc., the US Court of Appeals for the Federal Circuit denied Teva’s petition for rehearing by the three-judge panel that originally heard the case or by the court’s full slate of judges, in an order issued Monday. Circuit judges Leonard Stark and Pauline Newman, who is suspended, didn’t participate in deciding the rehearing petition.

The appeals ...